NTX-1088 is under clinical development by Nectin Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NTX-1088’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NTX-1088 is under development for the treatment of solid tumors. It acts by targeting PVR/CD155. It is administered through intravenous route.
Nectin Therapeutics overview
Nectin Therapeutics is a biotechnology company that develops immune oncology (IO) therapies for cancer. The company is investigating its pipeline programs including NTX1088, an immune checkpoint inhibitor; and NTX2R13, a novel immune inhibitory receptor for the treatment of solid tumour; and NTX1107 targeting hematological and solid tumors. It utilizes novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs) to develop immune oncology therapies. Nectin Therapeutics works in collaboration with pharmaceutical and biotechnology companies to develop novel therapies in the areas of oncology. The company funding partners include Cancer Focus Fund, aMoon Fund, Peregrine Ventures and Integra Holdings. It has operational presence in the US. Nectin Therapeutics is headquartered in Jerusalem, Israel.
For a complete picture of NTX-1088’s drug-specific PTSR and LoA scores, buy the report here.